ASX/200 Closer Higher by 1.37%, Lifted by Healthcare

By the end of the trading session on 18 July 2025, the benchmark index S&P/ASX 200 closed higher by 1.37% and settled at 8,757.20. All 11 sectors ended higher along with the S&P/ASX 200.

Healthcare and Materials are the top-gaining sector, gaining 2.47% and 2.06% in their it’s value.

Mesoblast Limited (ASX: MSB) and Clarity Pharmaceuticals Limited (ASX: CU6) are the top-gaining stocks, gaining 34.636% and 11.781% in their stock prices. On the other hand, Yancoal Australia Limited (ASX: YAL) and Medibank Limited (ASX: MPL) are the top-losing stocks, losing 5.807% and 2.525% in their stock prices.

Copyright © 2022 Kapitales Research

Top gainer for the day:

• Healthcare (Up 2.47%)
• Materials (Up 2.06%)

Other Factors influencing the market:

• Mesoblast Limited (ASX: MSB) surged 34.7% to $2.41 after announcing promising initial sales of its cell therapy product Ryoncil, which entered the market in March.
• Atlas Arteria (ASX: ALX) dipped 0.4% to $5.15 following a legal setback in the Virginia Supreme Court, where it failed to gain approval for a proposed toll hike of up to 40% on the Dulles Greenway near Washington, D.C.
• Virgin Australia (ASX: VAH) rose 1.9% to $3.27 as UBS began coverage with a buy rating and a price target of $3.90, highlighting improved strategy, stronger financials, and a more efficient structure post-relisting.
• Iron ore prices have climbed to their highest level since early April, driven by optimism after BHP CEO Mike Henry noted continued strength in global commodity demand, particularly from China.
• Crude oil gained ground after a three-day decline, supported by solid U.S. retail data and lingering concerns over supply tightness.
• Global Market Snapshot: Dow Jones +0.52%, S&P 500 +0.54%, and NASDAQ Composite +0.75%
• Asian and European Markets: Hang Seng Index +0.89% and FTSE 100 +0.52%.

Top 5 Gainers and Losers Scoreboard:

90-Day Average Volume Outlier:

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com